Founded in 2000 by Dr. Ravinder Dhallan, Ravgen is a biotechnology company based in Columbia, Maryland, specializing in non-invasive prenatal diagnostic testing. The company's core mission is to provide safer, more accurate prenatal testing options by analyzing fetal DNA present in maternal blood. Ravgen offers a range of services, including non-invasive prenatal paternity DNA testing and genetic testing for single gene disorders and chromosomal abnormalities such as cystic fibrosis, spinal muscular atrophy, and sickle cell anemia. Their market focus is on expectant parents seeking early and reliable prenatal diagnostics.
Notable figures affiliated with Ravgen include its founder and CEO, Dr. Ravinder Dhallan. The company has made significant strides in the field of prenatal diagnostics, earning recognition for its innovative approach to non-invasive testing. Ravgen's technology has had a profound impact on prenatal care by reducing the risks associated with traditional invasive testing methods, thereby improving the safety and accuracy of prenatal diagnostics for both mothers and their unborn children.
